Increlex study aims to validate microdialysis for local IGF-I pharmacokinetics in Type 1 Diabetes

Disturbances in the GH-IGF-I axis are considered crucial for the deterioration of glycemic control in Type 1 Diabetes Mellitus (T1DM), particularly in adolescents. This imbalance may contribute to the development of insulin resistance and long-term microvascular complications. Current insulin therapy, delivered subcutaneously, leads to peripheral insulin excess and relative hepatic deficiency, differing from physiological pancreatic insulin delivery. Correcting the imbalance in circulating and tissue-specific IGF-I levels could potentially improve metabolic control and prevent early diabetic complications.

This randomized, single-blind, placebo-controlled crossover study enrolled 8 adolescents and young adults (18-23 years) with Type 1 Diabetes Mellitus. Participants received either a single subcutaneous injection of Increlex 120 micrograms/kg body weight or a placebo (0.1 ml of 0.9% Saline). The primary aim was to validate the microdialysis technique as a tool to predict local biological effects of IGF-I and to understand the pharmacokinetics of local IGF-I actions after SC injection. Whole-body glucose utilization was assessed using euglycemic clamp conditions, and interstitial muscle IGF-I concentrations were measured.

The abstract primarily outlines the study's aims and methodology rather than reporting specific quantitative findings or results. It states the investigation's purpose was to validate the microdialysis technique for assessing local biological effects of IGF-I and to characterize the pharmacokinetics of local IGF-I after subcutaneous Increlex administration in Type 1 Diabetes Mellitus patients. No data on glucose infusion rates, changes in IGF-I concentrations, or statistical significance values were provided within the abstract. Therefore, no specific numerical outcomes or direct conclusions regarding IGF-I's effect on muscle glucose uptake can be reported from this abstract.